Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wix.Com Ltd — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B), while Wix.Com Ltd trades at $74.59 (market cap $3.05B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 41.8× Wix.Com Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Wix.Com Ltd for 62 Days on average.
| VRTX | WIX | |
|---|---|---|
Market Cap | $127.55B | $3.05B |
Volume | 1,487,944 | 748,691 |
Sector | Health | Technology |
52-Week High | $557.96 | $145.54 |
52-Week Low | $407.37 | $40.43 |
Typical Hold Time | 120 Days | 62 Days |
Enterprise Value | $121.68B | $4.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Wix.com trades at $74.13, showing modest daily gains of 0.3%. The stock faces technical headwinds with a bearish moving average signal and RSI near overbought levels at 72.1. Fundamentally, revenue growth continues with 2025 reaching $1.99B, though profitability remains inconsistent with a negative net income margin of -8.19% in 2026. Analyst sentiment remains positive with 63% buy ratings and a $77 consensus target, but multiple class action lawsuits filed in September 2026 create near-term uncertainty.
Wix presents a mixed investment case with strong revenue growth offset by profitability challenges. The 3.9% upside to consensus target suggests modest near-term potential, but legal overhangs and volatile earnings create significant risk. Investors should weigh the company's market position against execution risks and legal uncertainties before establishing positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
